Obesity in the spotlight (part III)

Assessing deep impact of GLP-1s across all related biotech markets (CV, NASH, insulin pumps, etc.)

As a professor, many of my current and former colleagues are quite interested in obesity. Although my lab works primarily in cardiovascular/renal/metabolic diseases, I’ll never forget when one of my former colleagues (Dr. Lou Philipson) at the University of Chicago said “if we can solve obesity, we can solve diabetes.” In fact, a lot of the content I …